TANGO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.38 USD | +5.04% |
|
+31.01% | -5.25% |
Presenter SpeechChris Shibutani (Analysts)Okay. Let's get underway. Good afternoon, everybody....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.38
USD
Average target price
14.86
USD
Spread / Average Target
+58.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.25% | 100.22Cr | |
| +38.66% | 5.28TCr | |
| -7.81% | 3.89TCr | |
| +35.48% | 3.82TCr | |
| -10.77% | 2.68TCr | |
| +11.77% | 2.62TCr | |
| -17.82% | 1.99TCr | |
| +35.09% | 1.32TCr | |
| +29.17% | 1.22TCr | |
| -3.05% | 1.18TCr |
- Stock Market
- Equities
- TNGX Stock
- News Tango Therapeutics, Inc.
- Transcript : Tango Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02
